Stereotaxis has announced a strategic partnership with CardioFocus to accelerate the development and commercialization of robotic pulsed field ablation (PFA) technology for the treatment of cardiac arrhythmias.
Through this collaboration, the two companies will combine their proprietary platforms to bring to market the first-ever robotic PFA solution for cardiac ablation — integrating CardioFocus’ advanced PFA system with Stereotaxis’ robotic navigation expertise.
CardioFocus is the developer of the Centauri PFA System, a CE-marked open-platform technology that has been used to treat more than 9,000 patients across Europe. The system supports focal contact force catheter workflows and uses a custom monopolar waveform designed to create transmural lesions while eliminating microbubbles and muscle stimulation. This approach enables durable lesion formation, while improving procedural efficiency, safety, and patient outcomes.
Stereotaxis, on the other hand, is known for pioneering robotic magnetic navigation (RMN) systems that enhance the precision and safety of cardiac ablation. Its technologies — including the Genesis RMN system and the MAGiC Sweep high-density electrophysiology mapping catheter — have been used to treat more than 150,000 ablation patients worldwide.
In this collaboration, the companies successfully paired the Centauri PFA system with Stereotaxis’ MAGiC robotic cardiac ablation catheter. They have already completed bench and preclinical testing, with recent studies demonstrating safe, efficient, and effective lesion delivery, as well as deep, durable lesions in ventricular tissue.
According to the companies, the agreement will facilitate clinical trials, ensure regulatory compatibility, and support the commercial rollout of this pioneering robotic PFA technology — a milestone that could redefine precision electrophysiology and arrhythmia treatment.
Also Read
